Combined Fluorescence-Guided Resection and Intracavitary Thermotherapy with Superparamagnetic Iron-Oxide Nanoparticles for Recurrent High-Grade Glioma: Case Series with Emphasis on Complication Management

Michael Schwake 1,*,†, Michael Müther 1,†‡, Ann-Katrin Bruns 1, Bastian Zinnhardt 2,3, Nils Warneke 1, Markus Holling 1‡, Stephanie Schipmann 1,4, Benjamin Brokinkel 1, Johannes Wölfer 5, Walter Stummer 1 and Oliver Grauer 6‡

Department of Neurosurgery, University Hospital Münster, 48149 Münster, Germany; michael.muether@ukmuenster.de (M.M.); ann-katrin.bruns@ukmuenster.de (A.-K.B.); nils.warneke@ukmuenster.de (N.W.); markus.holling@ukmuenster.de (M.H.); stephanie.schipmann@ukmuenster.de (S.S.); benjamin.brokinkel@ukuenster.de (B.B.); walter.stummer@ukmuenster.de (W.S.); European Institute for Molecular Imaging (EIMI), University of Münster, 48149 Münster, Germany; bastian.zinnhardt@ukmuenster.de

1 Biomarkers & Translational Technologies (BTT), Pharma Research & Early Development (pRED), F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
2 Department of Neurosurgery, Haukeland University Hospital, 5021 Bergen, Norway
3 Department of Neurosurgery, Hufeland Klinikum, 99974 Mühlhausen, Germany; johannes.woelfer@t-online.de
4 Department of Neurology for Institute of Translational Neurology, University Hospital Münster, 48149 Münster, Germany; oliver.grauer@ukmuenster.de
5 Correspondence: michael.schwake@ukmuenster.de; Tel.: +49-251-83-47472; Fax: +49-251-83-45646

† The authors contributed equally to this work.

Abstract: Background: Concepts improving local tumor control in high-grade glioma (HGG) are desperately needed. The aim of this study is to report an extended series of cases treated with a combination of 5-ALA-fluorescence-guided resection (FGR) and intracavitary thermotherapy with superparamagnetic iron oxide nanoparticles (SPION). Methods: We conducted a single-center retrospective review of all recurrent HGG treated with FGR and intracavitary thermotherapy (n = 18). Patients underwent six hyperthermia sessions in an alternating magnetic field and received additional adjuvant therapies on a case-by-case basis. Results: Nine patients were treated for first tumor recurrence; all other patients had suffered at least two recurrences. Nine patients received combined radiotherapy and thermotherapy. The median progression-free survival was 5.5 months and median overall survival was 9.5 months. Although no major side effects were observed during active treatment, 72% of the patients developed cerebral edema requiring steroid treatment or even surgical removal of the nanoparticles. In conclusion, the combination of fluorescence-guided resection and intracavitary thermotherapy provides a novel and promising treatment option for improving local tumor control in recurrent high-grade gliomas, but further refinements of the treatment protocol are needed to decrease major side effects.

Simple Summary: Recurrent high-grade gliomas are difficult to treat. Here, we report on our single-center experience in combining fluorescence-guided tumor resection with 5-ALA and local thermotherapy with superparamagnetic iron nanoparticles. In total, 18 patients were operated on and received thermotherapy with or without additional radiotherapy. The median progression-free survival was 5.5 months and median overall survival was 9.5 months. Although no major side effects were observed during active treatment, 72% of the patients developed cerebral edema requiring steroid treatment or even surgical removal of the nanoparticles. In conclusion, the combination of fluorescence-guided resection and intracavitary thermotherapy provides a novel and promising treatment option for improving local tumor control in recurrent high-grade gliomas, but further refinements of the treatment protocol are needed to decrease major side effects.
option for improving local tumor control in recurrent HGG. The development of cerebral edema is a major issue requiring further refinements of the treatment protocol.

**Keywords:** glioma; myeloid cells; nanoparticles; thermotherapy; fluorescence; inflammation

1. Introduction

In spite of guideline-adherent treatment, the prognosis of high-grade gliomas (HGG) is poor [1,2]. Over time, developments such as fluorescence-guided resection (FGR) [3,4], intraoperative neuro-monitoring (IOM) [5,6], intraoperative magnetic resonance imaging (ioMRI) [7,8] and novel treatment methods such as Tumor-Treating Fields (TTF) [9] have led to limited improvements of survival times.

Fluorescence-guided resection with 5-aminolevulinic acid (5-ALA) is currently the only approved and one of the most widely used procedures in adult glioma surgery. The efficacy of 5-ALA-assisted resection and its impact on the degree of resection, progression-free survival (PFS), and overall survival (OS) in primary cases have been demonstrated in numerous studies [3–5,10,11]. Stummer et al. identified a significantly higher OS when no residual tumor was visible after surgery (16.7 vs. 11.8 months, \( p < 0.0001 \)) [12]. Moreover, this method is based on the intracellular accumulation of fluorescent protoporphyrin IX (PpIX). This selective accumulation is the reason for the high sensitivity and specificity of the fluorescence signal [13–18], also in the case of recurrent malignant brain tumors [19].

Therapies for tumor recurrence are not well defined, and the overall level of evidence for available treatments is low. Current guideline recommendations include re-resection, re-irradiation, chemotherapy and experimental treatment options [20]. In recent years, several clinical trials have yielded only limited results [21,22]. Even though HGG affect the whole brain, most surgical cases recur locally at the margins of resection cavities [23,24]. Therefore, improving local tumor control is the aim of all local therapy strategies, such as locally applied chemotherapy [25] and photodynamic therapy (PDT) [23,26].

Early clinical trials demonstrated the effectiveness and safety of stereotactic application of superparamagnetic iron oxide nanoparticles (SPION) subjected to an alternating magnetic field (AMF) in combination with irradiation in patients with recurrent HGG [27,28]. SPION with AMF is an approved treatment within the European Union. Hyperthermia generated by SPION has been shown to possibly elicit a potent antitumor immune response [29–31] with enhanced infiltration of natural killer (NK) cells, macrophages, dendritic cells and CD4+ and CD8+ T cells [32].

One major technical issue with stereotactic application is the inadequate distribution of SPION [28]. Additionally, with stereotactic procedures, immediate cytoreductive treatment is not possible. With this in mind, we developed a novel technique of administering the particles into the resection cavity immediately after FGR. The main advantage of this method is that the surgeon has optimal control over particle distribution, enabling him to apply larger particle volumes while preventing spillage into the ventricles.

The primary aim of this study is to present our results concerning effectiveness and the outcome, in term of overall survival (OS), with the secondary objective to evaluate the safety of combined FGR and local intracavitary thermotherapy with superparamagnetic iron oxide nanoparticles in an extended series of patients treated at our center.

2. Methods

2.1. Patients

This case series includes all patients treated with a combination of FGR and intracavitary SPION thermotherapy in a single-center academic setting from 2015 to 2020 (Figure 1). All patients with recurrent HGG considered as candidates for surgical resection were offered additional intracavitary thermotherapy as an adjunctive treatment modality. Data analysis was performed retrospectively, with all procedures and analyses being approved by the
local ethics committee according to the declaration of Helsinki (2020-531-f-S). Informed consent was obtained from all subjects involved in the study.

Figure 1. Flow chart of treatment.

2.2. Nanoparticles

As previously reported [32], the semifluid solution MFL AS-1 (NanoTherm®, MagForce AG, Berlin, Germany) containing SPION with an iron concentration of 112 mg/mL was applied during surgery. The fluid is manufactured according to European medical device regulations and has been approved for the treatment of brain tumors since 2011.

2.3. Fluorescence-Guided Resection and Nanoparticle Application

Tumor resection was performed using a standard microsurgical technique. 5-aminolevulinic acid (5-ALA, Gliolan®, Medac GmbH, Wedel, Germany) was applied orally 4 h prior to anesthesia induction at a concentration of 20 mg/kg body weight. The surgical aim was to remove the fluorescent tumor. In cases with a motor-eloquent tumor location, dynamic MEP mapping was used for corticospinal tract mapping. Speech-eloquent tumors were resected under awake conditions for speech monitoring, as described previously [33]. After tumor resection, the cavity wall was coated with a hydroxyccellulose mesh (Tabotamp®, Johnson & Johnson Medical GmbH, Ethicon, Norderstedt, Germany), and subsequently SPION were applied to the hydroxyccellulose mesh using a 1 mL syringe. Up to three layers of hydroxyccellulose and SPION were applied, if possible. Additionally, a closed-end catheter (TK-01, MagForce AG, Berlin, Germany) was led through the particle deposits to allow temperature measurement during treatment in the AMF device (Nano-Activator®, MagForce AG, Berlin, Germany). The bone flap was re-fixed using absorbable, non-metal plates (SonicWeld Rx®, KLS Martin, Tuttlingen, Germany). Metallic body implants up to 40 cm from the tumor, including dental implants and bone flap fixation plates, were removed during surgery or were removed before. Patients in which tumor resection led to opening of the ventricle were not eligible for the application of nanoparticles to decrease the risk of unintended particle distribution within the CSF spaces.

Due to artifacts caused by the SPION, we could not rely on postoperative MRI scans when estimating the extent of resection (EOR). Therefore, we rated EOR as gross total resection (GTR) if all fluorescing tumor tissue was removed, near total resection (NTR)
whenever a weak and diffuse fluorescent signal was detected at the end of surgery, and subtotal resection (STR) if a strong and compact fluorescence signal had to be left over, e.g., in eloquent regions. Previous studies have proven a close association between the fluorescence signal and EOR on postoperative MRI [3, 5, 12].

2.4. Thermotherapy

After surgery, computed tomography (CT) was performed (Figure 2). These images were fused with preoperative MRI scans using the treatment simulation software NanoPlan® (MagForce AG), as published previously [32, 34–36]. NanoPlan® simulates heat generation as a function of the nanoparticle density and intensity of AMF. However, due to the lack of technical possibilities for measuring local tissue perfusion over the course of a hyperthermia application, this simulation tends to be imprecise. Therefore, temperature measurements must be performed during the treatment session to readjust the simulation. During the first hyperthermia application, a fiber-optic temperature sensor (Optocon, Dresden, Germany) was inserted into the closed-end catheter that was placed during surgery. Thermotherapy was performed in the AMF applicator operating at a frequency of 100 kHz and with field intensities of 2.5–15 kA/m, as published previously [32]. The highest temperature along the thermocatheter course was used to fine-tune the field strength. Two one-hour treatments were scheduled per week. In cases with concomitant radiotherapy, the first thermotherapy session was scheduled 3 days before the start of radiotherapy, while another five sessions were conducted at days 1, 4, 8, 11, 15 ± 1 day. Radiotherapy was performed as previously described [32] and, when planned for the same day, took place within a time interval of 2 h to each thermotherapy session.

![Figure 2](image_url)

**Figure 2.** (A) Magnetic resonance imaging performed preoperatively showing contrast-enhanced tumor in the right parietal lobe. (B) Contrast-enhanced computed tomography performed at the first postoperative day. (C) Computed tomography in patient 13 demonstrating significant edema two months after surgery.

2.5. Follow Up

As noted above, the placement of iron nanoparticles does not allow for adequate postoperative imaging with MRI. Patients who live close to our center were followed up with 18F-Fluoro-ethyl-tyrosine (18F-FET)-PET-CT, including post-contrast studies, once every three months. With all other patients, post-contrast CT scans were used for follow-up. If the nanoparticles had to be removed over the course of disease, MRI was again chosen as the optimal imaging modality. In order to further visualize the immunological response during thermotherapy, we conducted a N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide (18F-DPA-714) PET scan for translocator protein (TSPO) in individual cases, as previously described [37].

2.6. Data Analyses

The IBM SPSS Statistics 25.0 package (IBM, Armonk, New York, NY, USA) was used for statistical analyses. Data were analyzed by standard descriptive statistics, using absolute
and relative frequencies for categorical variables, median and interquartile range (IQR) for continuous variables, and mean and standard deviation (SD) for metrical variables. The Mann–Whitney U-Test (MWU) was used for ordinal and Fisher’s exact test for categorical variables. Time-to-event analyses were performed using Kaplan–Meier curves and log-rank test. Progression-free survival (PFS) defines the time from the procedure until progression according to modified RANO criteria or death [38]. Overall survival (OS) was defined as the time from procedure to death. A probability value less than 0.05 was considered statistically significant.

3. Results

Eighteen patients with recurrent HGG were treated with FGR and subsequent intracavitary thermotherapy. Eight patients (44%) were female. The median age was 51 years (IQR: 43–61). According to the WHO classification of 2006 [39], sixteen patients (89%) were diagnosed with glioblastoma, and each of the remaining two were diagnosed with anaplastic astrocytoma and anaplastic oligodendroglioma, respectively. Fourteen cases showed IDH wildtype (78%). The MGMT promotor was non-methylated in 13 cases (76%). Nine patients (50%) were treated for first tumor recurrence; all other patients suffered at least two recurrences (Table 1). The median time between initial diagnosis and surgical treatment investigated in this study was 14 months (IQR: 7–45). All patients received thermotherapy twice a week at a median temperature of 47.0°C (IQR: 44.5–53.3). Nine patients (50%) additionally received concurrent radiotherapy at a dose of 39.6 Gy (5 × 1.8 Gy/week); all other patients did not receive radiotherapy due to dose limitations (Figure 1). Initially, no salvage chemotherapy was administered. During follow-up, one patient received temozolomide and one patient received bevacizumab for palliative edema treatment (Table 2).

| ID  | Age (Years) | Sex | Initial Diagnosis                  | Time Since Initial Diagnosis (Months) | Number of Recurrences | Current Diagnosis                  | MGMT Promotor Location |
|-----|-------------|-----|------------------------------------|--------------------------------------|------------------------|------------------------------------|-------------------------|
| 1   | 42          | F   | Glioblastoma, IDH mutated          | 6                                    | 1                      | Glioblastoma, IDH mutated          | methylated LP           |
| 2   | 60          | M   | Glioblastoma, IDH wild type        | 13                                   | 2                      | Glioblastoma, IDH wild type        | unmethylated RP         |
| 3   | 59          | M   | Glioblastoma, IDH wild type        | 15                                   | 1                      | Glioblastoma, IDH wild type        | unmethylated LP         |
| 4   | 65          | M   | Glioblastoma, IDH wild type        | 8                                    | 2                      | Glioblastoma, IDH wild type        | unmethylated RP         |
| 5   | 75          | F   | Glioblastoma, IDH wild type        | 4                                    | 1                      | Glioblastoma, IDH wild type        | unmethylated RF         |
| 6   | 42          | M   | Glioblastoma, IDH wild type        | 3                                    | 4                      | Glioblastoma, IDH wild type        | methylated LF           |
| 7   | 63          | F   | Glioblastoma, IDH wild type        | 13                                   | 1                      | Glioblastoma, IDH wild type        | unmethylated LP         |
| 8   | 36          | F   | Anaplastic astrocytoma, IDH mutated| 57                                   | 2                      | Anaplastic astrocytoma, IDH mutated| unmethylated RF         |
| 9   | 38          | M   | Glioblastoma, IDH wildtype         | 42                                   | 2                      | Glioblastoma, IDH wildtype         | unmethylated LO         |
| 10  | 62          | M   | Glioblastoma, IDH wild type        | 7                                    | 1                      | Glioblastoma, IDH wildtype         | unmethylated LO         |
| 11  | 42          | F   | Glioblastoma, IDH wildtype         | 33                                   | 1                      | Glioblastoma, IDH wildtype         | unmethylated LO         |
| 12  | 40          | F   | Diffuse Astrocytoma, IDH mutated   | 248                                  | 3                      | Anaplastic Astrocytoma, IDH mutated| methylated RF           |
| 13  | 58          | M   | Glioblastoma, IDH wildtype         | 6                                    | 1                      | Glioblastoma, IDH wildtype         | unmethylated RP         |
| 14  | 44          | F   | Glioblastoma, IDH wildtype         | 8                                    | 1                      | Glioblastoma, IDH wildtype         | unmethylated LF         |
Table 1. Cont.

| ID | Age (Years) | Sex | Initial Diagnosis | Time Since Initial Diagnosis (Months) | Number of Recurrences | Current Diagnosis | MGMT Promotor Location |
|----|-------------|-----|-------------------|---------------------------------------|------------------------|-------------------|------------------------|
| 15 | 46          | M   | Glioblastoma, IDH wildtype | 10                                    | 1                      | Glioblastoma, IDH wildtype | unmethylated RP       |
| 16 | 57          | M   | Diffuse Astrocytoma, IDH mutated | 167                                   | 3                      | Anaplastic Oligodendroglioma, IDH mutated | not available LT       |
| 17 | 58          | F   | Glioblastoma, IDH wildtype | 16                                    | 3                      | Glioblastoma, IDH wildtype | unmethylated LT       |
| 18 | 45          | M   | Glioblastoma, NOS | 133                                   | 3                      | Glioblastoma, IDH mutated | methylated LT         |

R, right. L, left. F, frontal. P, parietal. T, temporal. O, occipital.

Table 2. Data on thermotherapy and follow up.

| Patient ID | EOR | Volume of Nanoparticles (mL) | Peak Temperature (°C) | Re-Irradiation (Gy) | Salvage Chemotherapy | Time to Edema (Months) | Revision Due to Edema | PFS (Months) | OS (Months) |
|------------|-----|-----------------------------|-----------------------|---------------------|----------------------|------------------------|----------------------|--------------|-------------|
| 1          | STR | 2.8                         | 59                    | -                   | -                    | 3.67                   | Yes                  | 72 †         | 72 †        |
| 2          | GTR | 3.2                         | 60                    | 39.6                | -                    | 0.33                   | No                   | 7            | 7           |
| 3          | NTR | 2                           | 56                    | 39.6                | -                    | 1.97                   | Yes                  | 11           | 24          |
| 4          | STR | 2.1                         | 53                    | 39.6                | -                    | 4.43                   | No                   | 5            | 7           |
| 5          | GTR | 5                           | 53                    | -                   | -                    | 3.46                   | No                   | 3            | 4           |
| 6          | NTR | 3                           | 54                    | -                   | -                    | 3.16                   | No                   | 3            | 5           |
| 7          | NRT | 3.2                         | 49                    | -                   | -                    | 3.97                   | No                   | 3            | 3           |
| 8          | GTR | 4.3                         | 44                    | -                   | Temozolomide         | 5.07                   | No                   | 35           | 35          |
| 9          | GTR | 3.4                         | 50                    | -                   | -                    | 2.87                   | No                   | 4            | 10          |
| 10         | GTR | 3.8                         | 48                    | 39.6                | Bevacizumab          | 3.33                   | No                   | 8            | 8           |
| 11         | NTR | 5                           | 45                    | 39.6                | -                    | 3.33                   | No                   | 5            | 10          |
| 12         | NTR | 7                           | 42                    | -                   | Non                  | 1.36                   | Yes                  | 6            | 7           |
| 13         | NTR | 7                           | 46                    | 39.6                | -                    | 1.5                    | Yes                  | 6            | 7           |
| 14         | GTR | 3                           | 39                    | 39.6                | -                    | 2.0                    | No                   | 5            | 6           |
| 15         | GTR | 1.9                         | 43.3                  | 39.6                | -                    | 2.33                   | Yes                  | 3            | 15 †        |
| 16         | NTR | 5                           | 45                    | -                   | Non                  | 0.77                   | No                   | 3            | 5           |
| 17         | STR | 5                           | 44.6                  | -                   | -                    | 1.83                   | Yes                  | 2            | 11          |
| 18         | STR | 5                           | 45                    | -                   | -                    | -                     | -                   | -            | -           |

EOR, extent of resection. GTR, gross total resection. NTR, near total resection. STR, subtotal resection. PFS, progression-free survival. OS, overall survival. † Patients without evidence of progression. †† patients still alive.

3.1. Survival Analysis

Tumor progression was defined according to the modified RANO criteria [38]. The median progression-free survival (PFS) for the study population was 5.5 months (95% CI: 4.67–6.13) after thermotherapy, and median overall survival (OS) was 9.5 months (95% CI: 7.12–11.79) (Figure 3). Survival differences could neither be observed between patients treated for first recurrence and patients treated for second recurrence or later (p = 0.283 for PFS; p = 0.608 for OS) nor in patients who received both thermotherapy and radiotherapy and those having received thermotherapy alone (p = 0.232 for PFS; p = 0.450 for OS).

Figure 3. Kaplan–Meier plots demonstrating progression-free survival (PFS) and overall survival (OS) in months, after fluorescence-guided resection (FGR) and thermotherapy. Strokes mark censored data points. Median progression-free survival (PFS) for the study population was 5.5 months (95% CI: 4.67–6.13) after thermotherapy and median overall survival (OS) was 9.5 months (95% CI: 7.12–11.79).
3.2. Safety and Complications

No major side effects were observed in the immediate perioperative phase or during AMF treatment. However, thirteen patients (72%) developed cerebral edema with clinical symptoms during treatment follow-up (median: 70 days, IQR: 50–105) and were treated with dexamethasone. In six of these thirteen cases (46%), nanoparticles had to be removed surgically due to refractory edema. Four (31%) of these developed impaired surgical site infections after prolonged treatment with steroids (median: 72 days, IQR: 59–116). One patient (No. 4) developed transient mild myelopathy, with cervical MRI suggesting a T2 hyperintense medullary heat injury caused by a small spinal deposit of dislocated nanoparticles (Figure 4).

Figure 4. T2-weighted magnetic resonance imaging of the cervical spine of patient 4 in sagittal (left) and axial (right) planes. Note the intramedullary hyperintense lesion of the spinal cord at the level of C2-3 adjacent to metal artefacts (arrow).

The mean peak temperature during treatments was 47 °C (IQR: 44.5–53.3). We found no significant association between peak temperature and edema development ($p > 0.05$). Moreover, no significant correlations between peak temperature and steroid treatment, reoperation, OS, PFS, or time interval to edema development (all $p > 0.05$) were found. Further analyses did not show any association between additional radiotherapy and the development of edema ($p > 0.05$).

4. Discussion

In this analysis of an extended case series, we evaluated the effectiveness, safety and technical issues of combined 5-ALA FGR and intracavitary thermotherapy. We found a median PFS of 5.5 months (95% CI: 4.67–6.13) and median OS of 9.5 months (95% CI: 7.12–11.79) after surgery and thermotherapy. In contrast to earlier studies, we did not observe a significant value of re-irradiation in combination with thermotherapy on OS and PFS [32,40–42]. Moreover, we found no significant difference between the survival outcomes of patients treated for their first recurrence vs. second recurrence or later.

As for now, there is no standard treatment for patients with recurrent HGG. Recent non-randomized trials show that patients may benefit from repeated resection with a median PFS of 1.9 months and OS of 6.5–12.9 months [43–46]. Re-irradiation was also associated with a modest survival benefit compared to best supportive care alone. Survival times could be improved when re-irradiation was combined with other treatment modalities (median OS of 8.2 months vs. 12.2 months) [47]. Regarding systemic treatments in recurrent GBM, therapeutic options include salvage chemotherapy with temozolomide, lomustine, bevacizumab or combinations, and regorafenib. A median PFS of 1.5–4.2 months and median OS of 6.0 to 10.6 months were reported [48–52]. Decision making is even more complex in cases of second or later recurrence. In general, thermotherapy is not a novel concept in neuro-oncology. Laser interstitial therapy (LITT), a stereotactic procedure
which is limited to smaller lesions, showed comparable survival outcomes for recurrent glioblastoma [53,54]. Recently, our group also published a series of recurrent glioblastoma patients treated with intraoperative open photodynamic therapy after FGR with comparable survival curves [23]. Importantly, in comparison to other modalities, NanoTherm® nanoparticles have been certified according to the European medical device regulations for the treatment of brain tumors since 2011. Moreover, intracavitary nanoparticle application allows one to address more complex tumor architecture and can be directly combined with microsurgical resection.

4.1. Combining FGR with Application of Nanoparticles

In comparison to the classical stereotactic application of nanoparticles [27], its addition to fluorescence-guided resection has several advantages. Cytoreduction using FGR and IOM shows good oncological and functional results [55]. This allows us to provide thermotherapy in addition to the best standard of care. As opposed to stereotactic application of nanoparticles, higher volumes of nanoparticles can be applied without causing elevated intracranial pressure. Moreover, as an open procedure enables the neurosurgeon to distribute the particles more accurately under direct visual control, common problems connected to the stereotactic method including leakage and backwash of the nanoparticles, which can be avoided. Finally, with one surgical corridor, there is no need for multiple trajectories, which are required in cases of larger tumors with stereotactic application alone [27,28].

4.2. Complication Management

After a short period of time (median: 70 days, IQR: 50–105) more than half of the patients developed perifocal edema with additional neurological deficits, requiring treatment with higher steroid doses. In six of these cases, nanoparticles had to be removed surgically due to refractory edema (n = 6; 33%). In our previous publication we focused on the immunological aspect of this reaction that must be considered as part of the treatment. In histopathology, brain tissue revealed large amounts of aggregated nanoparticles located in necrotic tissue without evidence of tumor activity. At the borders, nanoparticles were found to be incorporated by phagocytes. The surrounding tissue exhibited a strongly proinflammatory state with increased T cell, NK cell and myeloid cell infiltration [32]. These reactions were also found in this case series (patients 9 and 13). As well as edema formation, four patients also developed surgical site infection, probably due the prolonged treatment with steroids (n = 4; 22%). Therefore, the administration of high doses of corticosteroids (dexamethasone more than 4 mg/day) for a longer period (>6 weeks) should be avoided. As an alternative, bevacizumab could be used for edema control, as has been demonstrated for the treatment of radionecrosis [56].

Otherwise, the surgical removal of the nanoparticles and of necrotic tissue bulbs from the tumor core must be discussed. In addition, thermotherapy should be limited to patients who are not in need of corticosteroids before treatment starts. Moreover, patients with compromised clinical performance status who may not tolerate temporary increases in edema secondary to necrosis, or are in risk of other major side effects, will not be eligible for this therapy—as is also the case for all other therapies.

In comparison to stereotactic applications [27,28], nanoparticle application after tumor resection allows for a much better distribution and higher concentration of nanoparticles at the borders of the tumor cavity. Yet, elution into the ventricles and basal cisterns must be avoided to prevent complications such as in patient 4. Therefore, any contacts between the resection cavity and ventricles or cisterns should be sealed, e.g., using fibrinogen-coated collagen pads, if possible.

4.3. Outlook

As hyperthermia must be assumed to be the major cause for edema formation, special attention must be directed to temperature simulation and adjustment. Currently, the maximum temperature registered along the course of the closed-end catheter is used to
correct the simulation and to tune the AMF. It might be more reasonable to adjust the AMF according to the temperature at the tumor–SPION border, for this is the region in which biological heat effects are expected to be the most pronounced.

We are working on solutions to measure temperatures simultaneously at multiple sites along the thermometry catheter, which should preferably be positioned along the rim of the tumor cavity. These measurements will be used for real-time corrections of the temperature simulation to create a more precise temperature chart. Another option might be to place a second catheter to obtain more reference points for the simulation. It is not easy to envision, but most the desirable process for accurate therapy steering would be a non-invasive method able to create a three-dimensional temperature chart under the conditions of a high-energy alternating magnetic field.

The main determinants of tissue heat generation are field strength, nanoparticle density and tissue perfusion. A standard perfusion value averaged over the whole brain is currently used for temperature simulation. Because of postoperative scarring, necrosis, varying cell densities or preexisting edema, etc., local perfusion will almost always differ from this generalized assumption. As brain perfusion mapping can be easily and routinely accomplished using dynamic contrast CT techniques, the NanoPlan® software is currently modified to include this modality for a voxel-based correction of the simulation.

A higher number of nanoparticle sheets allows for lower AMF energy, which facilitates field strength adjustments during treatment sessions. However, too large volumes may foster space-occupying necrotic reactions with post-treatment edema, as seen in case number 13 (Table 2). More highly concentrated SPION solutions might be engineered to address this problem.

One novel option to demonstrate and monitor post-treatment inflammatory reactions and the immunologic tumor microenvironment (TME) is dual-tracer PET imaging with ¹⁸F-FET and ¹⁸F-DPA-714 (a ligand of microglial translocator protein (TSPO)). In the case of patient 8, this imaging was conducted six months after thermotherapy (Figure 5). TSPO signaling clearly exceeded the FET signal, which might indicate the activation of glioma-associated myeloid cells beyond the tumor borders delineated by FET-PET. Combining these imaging biomarkers supports the characterization of the TME, as discussed in an earlier study [37]. Regarding thermotherapy, TSPO imaging shows perifocal immunologic reactions that clearly exceed solid tumor volumes. Therefore, TSPO PET may contribute to a more elaborate classification of recurrence that helps the clinician to perfectly tailor the thermotherapy settings [57].

Figure 5. Patient 8, six months after completion of thermotherapy. Combination of CT post contrast (A), ¹⁸F-FET- (B) and ¹⁸F-DPA-714-PET (C) imaging. Note the increasing volumes of contrast enhancement, FET positivity and DPA positivity, respectively; the latter is referring to the infiltration of myeloid cells within the tumor microenvironment.
At present, we assume that FGR and intracavitary thermotherapy are a good alternative treatment option for patients with recurrent and resectable HGG in non-eloquent regions with moderate edema. This particularly includes HGG patients at first recurrence with a non-methylated MGMT promoter and tumor progression during the treatment with alkylating agents, but also HGG patients with second or later recurrence. However, our results are based on a retrospective review of a heterogenous series of recurrent HGG. Further investigations are necessary to refine several technical aspects, such as the applied SPION volume, or the calculation and monitoring of therapy temperature. Recently, a patient registry has been established to collect treatment data prospectively.

5. Conclusions

FGR in combination with intracavitary thermotherapy is an interesting treatment modality for patients with malignant glioma. In addition to cytoreductive treatment, non-ablative hyperthermia can induce an inflammatory reaction; however, the frequent development of cerebral edema requires the refinement of the treatment protocol.

Author Contributions: Conceptualization, M.S., M.M., J.W., O.G.; Methodology, M.S. and M.M.; Software, M.S. and M.M.; Validation, S.S., J.W., O.G., W.S. and B.Z.; Formal Analysis, M.S., M.M., B.Z. and O.G.; Investigation, M.S. and J.W.; Resources, M.S., A.-K.B. and J.W.; Data Curation, M.S., A.-K.B. and B.Z.; Writing—Original Draft Preparation, M.S. and M.M.; Writing—Review and Editing, M.S., M.M., S.S., M.H., B.B., N.W., J.W., W.S. and O.G.; Visualization, M.S. and M.M.; Supervision, W.S.; Project Administration, M.S., J.W. and W.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of University of Münster, Germany (2020-531-f-S and date of approval: 18 August 2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All data generated or analysed during this study are included in this published article.

Conflicts of Interest: Walter Stummer reports lecture activities for Medac (Wedel, Germany), Carl Zeiss Meditech (Oberkochen, Germany) and MagForce AG (Berlin, Germany). Oliver Grauer has received financial support from MagForce AG (Berlin, Germany) for attending symposia. Michael Schwake and Stephanie Schipmann report consultant activities for MagForce AG (Berlin, Germany). All other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.

References

1. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [CrossRef] [PubMed]
2. Goldbrunner, R.; Minniti, G.; Preusser, M.; Jenkinson, M.D.; Sallabanda, K.; Houdart, E.; von Deimling, A.; Stavrinou, P.; Lefranc, F.; Lund-Johansen, M.; et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016, 17, e383–e391. [CrossRef]
3. Stummer, W.; Pichlmeyer, U.; Meinel, T.; Wiestler, O.D.; Zanella, F.; Reulen, H.; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7, 392–401. [CrossRef]
4. Stummer, W.; Novotny, A.; Stepp, H.; Goetz, C.; Bise, K.; Reulen, H. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. J. Neurosurg. 2000, 93, 1003–1013. [CrossRef]
5. Schucht, P.; Beck, J.; Abu-Isa, J.; Anderegggen, L.; Murek, M.; Seidel, K.; Stiegler, L.; Raabe, A. Gross Total Resection Rates in Contemporary Glioblastoma Surgery. Neurosurgery 2012, 71, 927–936. [CrossRef]
6. Seidel, K.; Beck, J.; Stiegler, L.; Schucht, P.; Raabe, A. The warning-sign hierarchy between quantitative subcortical motor mapping and continuous motor evoked potential monitoring during resection of supratentorial brain tumors; Clinical article. J. Neurosurg. 2013, 118, 287–296. [CrossRef]
29. Yanase, M.; Shinkai, M.; Honda, H.; Wakabayashi, T.; Yoshida, J.; Kobayashi, T. Antitumor Immunity Induction by Intracellular Hyperthermia Using Magnetite Cationic Liposomes. *Jpn. J. Cancer Res.* 1998, 89, 775–782. [CrossRef]

30. Ito, A.; Shinkai, M.; Honda, H.; Yoshikawa, K.; Saga, S.; Wakabayashi, T.; Yoshida, J.; Kobayashi, T. Heat shock protein 70 expression induces antitumor immunity during intracavitary hyperthermia using magnetite nanoparticles. *Cancer Immunol. Immunother.* 2003, 52, 80–88. [CrossRef]

31. Tanaka, K.; Ito, A.; Kobayashi, T.; Kawamura, T.; Shimada, S.; Matsumoto, K.; Saida, T.; Honda, H. Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. *Int. J. Cancer* 2005, 116, 624–633. [CrossRef]

32. Grauer, O.; Jaber, M.; Hess, K.; Weckesser, M.; Schwindt, W.; Maring, S.; Wölfer, J.; Stummer, W. Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients. *J. Neurooncol.* 2019, 141, 83–94. [CrossRef]

33. Molina, E.S.; Schipmann, S.; Mueller, I.; Wölfer, J.; Ewelt, C.; Maas, M.; Brokinkel, B.; Stummer, W. Conscious sedation with dexmedetomidine compared with asleep-awake-asleep craniotomies in glioma surgery: An analysis of 180 patients. *J. Neurosurg.* 2018, 129, 1223–1230. [CrossRef]

34. Plotkin, M.; Gneveckow, U.; Meier-Hauff, K.; Amthauer, H.; Feußner, A.; Denecke, T.; Gutberlet, M.; Jordan, A.; Felix, R.; Wust, P. 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. *Int. J. Hyperth.* 2006, 22, 319–325. [CrossRef]

35. Yoo, T.S.; Ackerman, M.J.; Lorenzen, W.E.; Schroeder, W.; Chalana, V.; Aylward, S.; Metaxas, D.; Whitaker, R. Engineering and algorithm design for an image processing API: A technical report on ITK—The Insight Toolkit. *Stud. Health Technol. Inform.* 2002, 85, 586–592. [CrossRef]

36. Gneveckow, U.; Jordan, A.; Scholz, R.; Brüss, V.; Waldöfner, N.; Ricke, J.; Feussner, A.; Hildebrandt, B.; Rau, B.; Wust, P. Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. *Med. Phys.* 2004, 31, 1444–1451. [CrossRef]

37. Zinnhardt, B.; Müther, M.; Roll, W.; Backhaus, P.; Jeibmann, A.; Foray, C.; Barca, C.; Döring, C.; Tavitian, B.; Dollé, F.; et al. TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. *Neuro. Oncol.* 2020, 22, 1030–1043. [CrossRef]

38. Wen, P.Y.; Macdonald, D.R.; Reardon, D.A.; Cloughesy, T.F.; Sorensen, A.G.; Galanis, E.; DeGroot, J.; Wick, W.; Gilbert, M.R.; Lassman, A.B.; et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. *J. Clin. Oncol.* 2010, 28, 1963–1972. [CrossRef]

39. Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. *Acta Neuropathol.* 2016, 131, 803–820. [CrossRef]

40. Issels, R.D.; Lindner, L.H.; Verweij, J.; Wust, P.; Reichardt, P.; Schem, B.C.; Abdel-Rahman, S.; Daugaard, S.; Salat, C.; Wendtner, C.M.; et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study. *Lancet Oncol.* 2010, 11, 561–570. [CrossRef]

41. Thiesen, B.; Jordan, A. Clinical applications of magnetic nanoparticles for hyperthermia. *Int. J. Hyperth.* 2008, 24, 467–474. [CrossRef] [PubMed]

42. Van Der Zee, J.; González González, D.; Van Rhoon, G.C.; Van Dijk, J.D.P.; Van Putten, W.L.J.; Hart, A.A.M. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. *Lancet* 2000, 355, 1119–1125. [CrossRef]

43. Ringel, F.; Pape, H.; Sabel, M.; Krex, D.; Bock, H.C.; Misch, M.; Weyerbrock, A.; Westermaier, T.; Senft, C.; Schucht, P.; et al. Clinical benefit from resection of recurrent glioblastomas: Results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. *Neuro. Oncol.* 2016, 18, 96–104. [CrossRef] [PubMed]

44. Chaichana, K.L.; Zadnik, P.; Weinart, J.D.; Olivi, A.; Gallia, G.L.; Blakeley, J.; Lim, M.; Brem, H.; Quiñones-Hinojosa, A. Multiple resections for patients with glioblastoma: Prolonging survival. *J. Neurosurg.* 2013, 118, 812–820. [CrossRef]

45. Helseth, R.; Helseth, E.; Johannesen, T.B.; Langberg, C.W.; Lote, K.; Renning, P.; Scheie, D.; Vik, A.; Meling, T.R. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. *Neuro. Oncol.* 2016, 18, 549–556. [CrossRef]

46. Shih, W.; Scannell Bryan, M.; Gilbert, M.R.; Mehta, M.P.; Blumenthal, D.T.; Brown, P.D.; Valeinis, E.; Hopkins, K.; Souhami, L.; Andrews, D.W.; et al. Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. *Int. J. Radiat. Oncol. Biol. Phys.* 2018, 100, 38–44. [CrossRef] [PubMed]

47. Perry, J.R.; Belanger, K.; Mason, W.P.; Fulton, D.; Kavan, P.; Easaw, J.; Shields, C.; Kirby, S.; Macdonald, D.R.; Eisenstat, D.D.; et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. *J. Clin. Oncol.* 2010, 28, 2051–2057. [CrossRef] [PubMed]
49. Weller, M.; Tabatabai, G.; Küstner, B.; Felsberg, J.; Steinbach, J.P.; Wick, A.; Schnell, O.; Hau, P.; Herrlinger, U.; Sabel, M.C.; et al. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. *Clin. Cancer Res.* 2015, 21, 2057–2064. [CrossRef]

50. Batchelor, T.T.; Mulholland, P.; Neyns, B.; Nabors, L.B.; Campone, M.; Wick, A.; Mason, W.; Mikkelsen, T.; Phuphanich, S.; Ashby, L.S.; et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. *J. Clin. Oncol.* 2013, 31, 3212–3218. [CrossRef]

51. Friedman, H.S.; Prados, M.D.; Wen, P.Y.; Mikkelsen, T.; Schiff, D.; Abrey, L.E.; Yung, W.K.A.; Paleologos, N.; Nicholas, M.K.; Jensen, R.; et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. *J. Clin. Oncol.* 2009, 27, 4733–4740. [CrossRef]

52. Lombardi, G.; De Salvo, G.; Brandes, A.; Eoli, M.; Rudà, R.; Faedi, M.; Lolli, I.; Pace, A.; Daniele, B.; Pasqualetti, F.; et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet. Oncol.* 2019, 20, 110–119. [CrossRef]

53. Diaz, R.; Ivan, M.E.; Hanft, S.; Vanni, S.; Manzano, G.; Jagid, J.; Komotar, R.J. Laser Interstitial Thermal Therapy. *Neurosurgery* 2016, 79, S3–S7. [CrossRef]

54. Munoz-Casabella, A.; Alvi, M.A.; Rahman, M.; Burns, T.C.; Brown, D.A. Laser Interstitial Thermal Therapy for Recurrent Glioblastoma: Pooled Analyses of Available Literature. *World Neurosurg.* 2021, 153, 91–97.e1. [CrossRef]

55. Chohan, M.O.; Berger, M.S. 5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas. *J. Neurooncol.* 2019, 141, 517–522. [CrossRef]

56. Levin, V.A.; Bidaut, L.; Hou, P.; Kumar, A.J.; Wefel, J.S.; Bekele, B.N.; Prabhu, S.; Loghin, M.; Gilbert, M.R.; Jackson, E.F. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. *Int. J. Radiat. Oncol. Biol. Phys.* 2011, 79, 1487–1495. [CrossRef]

57. Haider, A.S.; van den Bent, M.; Wen, P.Y.; Vogelbaum, M.A.; Chang, S.; Canoll, P.D.; Horbinski, C.M.; Huse, J.T. Toward a standard pathological and molecular characterization of recurrent glioma in adults: A Response Assessment in Neuro-Oncology effort. *Neuro. Oncol.* 2020, 22, 450–456. [CrossRef]